Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADPT Adaptive Biotechnologies Corp

Trading 07-24 12:42:44 EDT

22.35

+0.04

+0.18%

High22.77	Low21.83	Vol1.01M
Open22.56	D1 Closing22.31	Amplitude4.21%
Mkt Cap3.57B	Tradable Cap2.82B	Total Shares159.76M
T/O22.45M	T/O Rate0.80%	Tradable Shares126.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADPT","market":"US","secType":"STK","nameCN":"Adaptive Biotechnologies Corp","latestPrice":22.35,"timestamp":1784911360733,"preClose":22.31,"halted":0,"volume":1011495,"delay":0,"changeRate":0.0017929179740028105,"floatShares":126000000,"shares":159760700,"eps":-0.325352,"marketStatus":"Trading","change":0.04,"latestTime":"07-24 12:42:44 EDT","open":22.56,"high":22.77,"low":21.83,"amount":22450859.801400002,"amplitude":0.042134,"askPrice":22.36,"askSize":327,"bidPrice":22.34,"bidSize":238,"shortable":3,"etf":0,"ttmEps":-0.325352,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1784923200000},"marketStatusCode":2,"adr":0,"listingDate":1561608000000,"exchange":"NASDAQ","adjPreClose":22.31,"preHourTrading":{"tag":"盘前","latestPrice":21.5187,"preClose":22.31,"latestTime":"07:55 EDT","volume":25,"amount":559.3587,"timestamp":1784894114807,"change":-0.7913,"changeRate":-0.035468,"amplitude":0.039951},"postHourTrading":{"tag":"盘后","latestPrice":22.19,"preClose":22.31,"latestTime":"19:34 EDT","volume":204753,"amount":4584669.745,"timestamp":1784849649983,"change":-0.12,"changeRate":-0.005379,"amplitude":0.015016},"volumeRatio":0.730099,"impliedVol":0.8077,"impliedVolPercentile":0.4661},"requestUrl":"/m/hq/s/ADPT/","defaultTab":"news","newsList":[{"id":"1169811047","title":"Earning Preview: Adaptive Biotechnologies Corp Q2 revenue is expected to increase by 33.37%, and institutional views are predominantly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1169811047","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1169811047?lang=en_us&edition=fundamental","pubTime":"2026-07-23 00:55","pubTimestamp":1784739302,"startTime":"0","endTime":"0","summary":"Abstract Adaptive Biotechnologies Corp will release its quarterly results on July 29, 2026 (Post-Mkt), with consensus pointing to revenue of 65.89 million US dollars and adjusted EPS of -0.13, while...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Adaptive Biotechnologies Corp Q2 revenue is expected to increase by 33.37%, and institutional views are predominantly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653774168","title":"Adaptive Biotechnologies CSO Harlan S. Robins Reports Disposal of Common Shares Worth $10.77 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2653774168","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653774168?lang=en_us&edition=fundamental","pubTime":"2026-07-24 07:35","pubTimestamp":1784849727,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies CSO Harlan S. Robins reports disposal of common shares worth $10.77 millionAdaptive Biotechnologies Chief Scientific Officer Harlan S. Robins exercised options for 284,800 com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL5cmyfR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies CSO Harlan S. Robins Reports Disposal of Common Shares Worth $10.77 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653938117","title":"Is Adaptive Biotechnologies (ADPT) Fully Valued As Its Zacks Upgrade Lifts Earnings Hopes?","url":"https://stock-news.laohu8.com/highlight/detail?id=2653938117","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653938117?lang=en_us&edition=fundamental","pubTime":"2026-07-23 03:34","pubTimestamp":1784748854,"startTime":"0","endTime":"0","summary":"Investor sentiment shift after earnings-focused rating upgrade\nAdaptive Biotechnologies (ADPT) is back on investors’ radar after a recent upgrade to a Zacks Rank #2 (Buy). The move is tied to higher earnings estimates and a more constructive view on its earnings outlook.\nSee our latest analysis for Adaptive Biotechnologies.\nThe recent Zacks upgrade comes as Adaptive Biotechnologies’ share price has rallied, with a 28.81% 1 month share price return and 59.01% 3 month share price return. Its 1...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/is-adaptive-biotechnologies-adpt-fully-valued-as-its-zacks-u","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/is-adaptive-biotechnologies-adpt-fully-valued-as-its-zacks-u","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653241139","title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 5,000 Shares for $115,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2653241139","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653241139?lang=en_us&edition=fundamental","pubTime":"2026-07-21 07:20","pubTimestamp":1784589629,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky disposes of 5,000 shares for $115,000Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky sold 5,000 common shares on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL41gDrl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 5,000 Shares for $115,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652330702","title":"Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of 105,762 Common Shares Worth $2.39 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2652330702","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652330702?lang=en_us&edition=fundamental","pubTime":"2026-07-18 07:24","pubTimestamp":1784330673,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief People Officer Francis Lo disposes of 105,762 common shares worth $2.39 millionAdaptive Biotechnologies Chief People Officer Francis Lo sold 105,762 shares on July 15 at","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL2NV8mT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of 105,762 Common Shares Worth $2.39 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","HELX","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650130361","title":"Adaptive Biotechnologies (ADPT) Stock Looks Reasonable On Cash Flow Yet Rich On Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2650130361","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650130361?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:41","pubTimestamp":1783716082,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies stock has delivered a very strong 196.2% return over the past three years, yet the current checks suggest it no longer looks obviously cheap. The Discounted Cash Flow (DCF) intrinsic value points to a roughly fair price, while market multiples lean rich.\n\nOver the last three years, Adaptive Biotechnologies has returned 196.2%, which puts extra attention on whether recent gains already reflect much of the good news.\nRegulatory use of the clonoSEQ assay in trials and...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-stock-looks-reasonable-on-cash","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-stock-looks-reasonable-on-cash","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650975200","title":"Adaptive Biotechnologies is Maintained at Equal-weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2650975200","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650975200?lang=en_us&edition=fundamental","pubTime":"2026-07-10 00:49","pubTimestamp":1783615740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings(END) Dow Jones NewswiresJuly 09, 2026 12:49 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","HELX","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650926335","title":"Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2650926335","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650926335?lang=en_us&edition=fundamental","pubTime":"2026-07-09 19:00","pubTimestamp":1783594849,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $20 from $18 and keeps an Equal Weight rating on the shares. Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-price-target-raised-to-20-from-18-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-price-target-raised-to-20-from-18-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650941044","title":"U.S. Research Roundup-applied Materials, CME Group, NASDAQ","url":"https://stock-news.laohu8.com/highlight/detail?id=2650941044","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650941044?lang=en_us&edition=fundamental","pubTime":"2026-07-09 15:28","pubTimestamp":1783582131,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Applied Materials, CME Group, NasdaqJuly 9 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S. listed companies, including Applied M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nL4N43B0KN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AX","AWR","ADPT","BOH","IXJ","ARTNA","AQWA","BLLN","TBBK","BX","XLV","ATEC","OWL","ALRS","TXG","FDFF","ACHC","ABBV","BLK","AFG","AIG","ADUS","APO","ALGN","BCS","RDVY","RXL","TECH","SHOC","AJG","ARES","BANR","TINY","AEE","BETR","AA","ARCB","AVAH","ALL","AXP","AMAT","AVAV","PSI","AFL","AWK","BAND","AR","ADP","IPAY","APH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649953160","title":"Adaptive Biotech CSO Harlan S. Robins Disposes of USD 8.49 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2649953160","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649953160?lang=en_us&edition=fundamental","pubTime":"2026-07-08 06:53","pubTimestamp":1783464813,"startTime":"0","endTime":"0","summary":"Adaptive Biotech CSO Harlan S. Robins disposes of USD 8.49 million in common sharesAdaptive Biotechnologies Chief Scientific Officer Harlan S. Robins sold 386,240 common shares on July 2, 2026.Sales p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDLt6cCv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotech CSO Harlan S. Robins Disposes of USD 8.49 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADPT","HELX","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649670565","title":"Does Russell Index Removal Reshape the Bull Case for Adaptive Biotechnologies (ADPT)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649670565","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649670565?lang=en_us&edition=fundamental","pubTime":"2026-07-07 08:32","pubTimestamp":1783384360,"startTime":"0","endTime":"0","summary":"On 27 June 2026, Adaptive Biotechnologies Corporation was removed from several Russell indices, including the Russell 3000E, Russell 3000E Growth Benchmark, Russell Microcap Index and Russell Microcap Growth Benchmark Index.\nThis broad index removal can alter how index-linked and institutional investors hold or trade Adaptive Biotechnologies, potentially reshaping the stock’s investor base and liquidity profile.\nWe’ll now examine how Adaptive Biotechnologies’ removal from multiple Russell...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/does-russell-index-removal-reshape-the-bull-case-for-adaptiv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/does-russell-index-removal-reshape-the-bull-case-for-adaptiv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HELX","ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649672129","title":"Adaptive Biotechnologies CCO Susan Bobulsky Sells 487 Shares Worth $10,714","url":"https://stock-news.laohu8.com/highlight/detail?id=2649672129","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649672129?lang=en_us&edition=fundamental","pubTime":"2026-07-07 07:16","pubTimestamp":1783379802,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies CCO Susan Bobulsky sells 487 shares worth $10,714Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky sold 487 common shares on July 1 at USD 22.Bobulsky held","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL4Vrgp2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Adaptive Biotechnologies CCO Susan Bobulsky Sells 487 Shares Worth $10,714","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648598420","title":"Adaptive Biotechnologies Chief Commercial Officer Imm Med Sharon Benzeno Sells 165,802 Shares for $3.73 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2648598420","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648598420?lang=en_us&edition=fundamental","pubTime":"2026-07-01 07:25","pubTimestamp":1782861942,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Commercial Officer Imm Med Sharon Benzeno sells 165,802 shares for $3.73 millionAdaptive Biotechnologies officer Sharon Benzeno, chief commercial officer, immune medicin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL1g8wN4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief Commercial Officer Imm Med Sharon Benzeno Sells 165,802 Shares for $3.73 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647588960","title":"Adaptive Biotechnologies Director Michelle Renee Griffin Disposes of 52,084 Common Shares Worth $1,051,855.12","url":"https://stock-news.laohu8.com/highlight/detail?id=2647588960","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647588960?lang=en_us&edition=fundamental","pubTime":"2026-06-30 07:50","pubTimestamp":1782777021,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies director Michelle Renee Griffin disposes of 52,084 common shares worth $1,051,855.12Adaptive Biotechnologies director Michelle Renee Griffin sold 52,084 common shares on June ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL7YxnJ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Director Michelle Renee Griffin Disposes of 52,084 Common Shares Worth $1,051,855.12","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647303075","title":"Adaptive Biotechnologies (ADPT) Plans A Business Split, Is The Valuation Already Full?","url":"https://stock-news.laohu8.com/highlight/detail?id=2647303075","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647303075?lang=en_us&edition=fundamental","pubTime":"2026-06-29 23:20","pubTimestamp":1782746449,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies (ADPT) is back in focus after announcing plans to separate its Minimal Residual Disease and Immune Medicine businesses, alongside completing a $300 million zero coupon convertible notes offering.\nSee our latest analysis for Adaptive Biotechnologies.\nThese separation plans and the recent convertible notes offering come on the back of strong momentum in Adaptive Biotechnologies' stock, with a 30 day share price return of 38.35% and a 1 year total shareholder return of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-plans-a-business-split-is-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/adaptive-biotechnologies-adpt-plans-a-business-split-is-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADPT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647377105","title":"Adaptive Biotechnologies is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2647377105","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647377105?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:06","pubTimestamp":1782741960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings(END) Dow Jones NewswiresJune 29, 2026 10:06 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647375409","title":"Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2647375409","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647375409?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:00","pubTimestamp":1782730824,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $22 from $21 and keeps a Buy rating on the shares. The firm adjuste...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-price-target-raised-to-22-from-21-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adaptive-biotechnologies-price-target-raised-to-22-from-21-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645008400","title":"Adaptive Biotechnologies Issues $345 Million Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2645008400","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645008400?lang=en_us&edition=fundamental","pubTime":"2026-06-23 05:38","pubTimestamp":1782164337,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies  said late Monday it has issued $345 million of 0% convertible senior notes due 2031, including the full exercise of an over-allotment option.Net proceeds were used among others for capped call transactions, share repurchase, and for the repayment of the OrbiMed purchase agreement, the company said in a filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645774300","title":"Adaptive Biotechnologies Corp - Issues $345 Mln in 0% Convertible Senior Notes Due 2031 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2645774300","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645774300?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:08","pubTimestamp":1782158918,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nFWN42U0LK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077439","title":"Adaptive Biotechnologies prices upsized USD 300 million 0% convertible senior notes offering due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077439","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645077439?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:07","pubTimestamp":1782158878,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies priced an upsized private offering of USD 300 million 0% convertible senior notes due 2031, raised from USD 250 million.Settlement is scheduled for June 22, 2026; initial purchasers hold an option to buy up to an additional USD 45 million of notes.Net proceeds estimated at about USD 290.8 million, or about USD 334.5 million if the option is fully exercised.Proceeds earmarked to repay the OrbiMed Purchase Agreement, fund a capped call, repurchase USD 25 million of stock, support MRD initiatives.Initial conversion price set at about USD 24.11 per share; capped call cap price set at USD 34.44.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLbwQ5DJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adaptivebiotech.com","stockEarnings":[{"period":"1week","weight":0.0095},{"period":"1month","weight":0.2948},{"period":"3month","weight":0.5778},{"period":"6month","weight":0.2027},{"period":"1year","weight":1.0524},{"period":"ytd","weight":0.3738}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.034},{"period":"6month","weight":0.071},{"period":"1year","weight":0.1639},{"period":"ytd","weight":0.0825}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.006662},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.034164},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.108302},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.084119},{"month":5,"riseRate":0.571429,"avgChangeRate":0.103614},{"month":6,"riseRate":0.857143,"avgChangeRate":0.145465},{"month":7,"riseRate":0.5,"avgChangeRate":0.004099},{"month":8,"riseRate":0.571429,"avgChangeRate":0.074393},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.065733},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.030408},{"month":11,"riseRate":0.714286,"avgChangeRate":0.049327},{"month":12,"riseRate":0.714286,"avgChangeRate":0.032336}],"exchange":"NASDAQ","name":"Adaptive Biotechnologies Corp","nameEN":"Adaptive Biotechnologies Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adaptive Biotechnologies Corp(ADPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adaptive Biotechnologies Corp,ADPT,Adaptive Biotechnologies Corp股票,Adaptive Biotechnologies Corp股票老虎,Adaptive Biotechnologies Corp股票老虎国际,Adaptive Biotechnologies Corp行情,Adaptive Biotechnologies Corp股票行情,Adaptive Biotechnologies Corp股价,Adaptive Biotechnologies Corp股市,Adaptive Biotechnologies Corp股票价格,Adaptive Biotechnologies Corp股票交易,Adaptive Biotechnologies Corp股票购买,Adaptive Biotechnologies Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adaptive Biotechnologies Corp(ADPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adaptive Biotechnologies Corp(ADPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction